专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

ZA200401850B 3-substituted-4-pyrimidone derivatives. 未知
公开(公告)号：ZA200401850B
公开(公告)日：2005-03-07
申请号：ZA200401850
申请日：2004-03-05
申请人： MITSUBISHI PHARMA CORP , SANOFI SYNTHELABO
发明人： UEHARA FUMIAKI , ARITOMO KEIICHI , SHODA AYA , HIKI SHINSUKE , OKUYAMA MASAHIRO , USUI YOSHIHIRO , OOIZUMI MITSURU , WATANABE KAZUTOSHI , YAMAKOSHI KOICHI
IPC分类号： A61K20060101 , A61P20060101 , C07D20060101 , C07D , A61K , A61P

2. 发明专利

PL368816A1 3-SUBSTITUTED-4-PYRIMIDONE DERIVATIVES 未知
公开(公告)号：PL368816A1
公开(公告)日：2005-04-04
申请号：PL36881602
申请日：2002-09-20
申请人： MITSUBISHI PHARMA CORP , SANOFI SYNTHELABO
发明人： UEHARA FUMIAKI , ARITOMO KEIICHI , SHODA AYA , HIKI SHINSUKE , OKUYAMA MASAHIRO , USUI YOSHIHIRO , OOIZUMI MITSURU , WATANABE KAZUTOSHI
IPC分类号： C07D239/36 , A61K31/513 , A61K31/5377 , A61K31/5386 , A61P3/04 , A61P3/10 , A61P17/14 , A61P25/02 , A61P25/16 , A61P25/18 , A61P25/28 , A61P27/02 , A61P27/06 , A61P35/00 , A61P35/02 , A61P43/00 , C07D239/34 , C07D239/40 , C07D239/46 , C07D239/56 , C07D401/04 , C07D401/14 , C07D413/04 , C07D413/14 , C07D417/14 , C07D498/10 , A61K31/505
摘要： A pyrimidone derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof having inhibitory activity against tau protein kinase 1: wherein R1 represents a C1-C12 alkyl group which may be substituted; R represents, for example, a group represented by the following formula (II): wherein R2 and R3 independently represent a hydrogen atom or a C1-C8 alkyl group; R4 represents a benzene ring which may be substituted, a naphthalene ring which may be substituted, an indan ring which may be substituted, a tetrahydronaphthalene ring which may be substituted, or an optionally substituted heterocyclic ring having 1 to 4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom, and having 5 to 10 ring-constituting atoms in total.

3. 发明专利

CA2460177A1 3-SUBSTITUTED-4-PYRIMIDONE DERIVATIVES 未知
公开(公告)号：CA2460177A1
公开(公告)日：2003-04-03
申请号：CA2460177
申请日：2002-09-20
申请人： MITSUBISHI PHARMA CORP , SANOFI SYNTHELABO
发明人： SHODA AYA , HIKI SHINSUKE , OKUYAMA MASAHIRO , ARITOMO KEIICHI , UEHARA FUMIAKI , OOIZUMI MITSURU , WATANABE KAZUTOSHI , USUI YOSHIHIRO
IPC分类号： C07D239/36 , A61K31/513 , A61K31/5377 , A61K31/5386 , A61P3/04 , A61P3/10 , A61P17/14 , A61P25/02 , A61P25/16 , A61P25/18 , A61P25/28 , A61P27/02 , A61P27/06 , A61P35/00 , A61P35/02 , A61P43/00 , C07D239/34 , C07D239/40 , C07D239/46 , C07D239/56 , C07D401/04 , C07D401/14 , C07D413/04 , C07D413/14 , C07D417/14 , C07D498/10 , A61K31/505
摘要： A pyrimidone derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof having inhibitory activity against tau protein kinase 1:wherein R1 represents a C1-C12 alkyl group which may be substituted;R represents, for example, a group represented by the following formula (II):wherein R2 and R3 independently represent a hydrogen atom or a C1- C8 alkyl group; R4 represents a benzene ring which may be substituted, a naphthalene ring which may be substituted, an indan ring which may be substituted, a tetrahydronaphthalene ring which may be substituted, or an optionally substituted heterocyclic ring having 1 to 4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom, and having 5 to 10 ring-constituting atoms in total.

4. 发明专利

CA2460177C 3-SUBSTITUTED-4-PYRIMIDONE DERIVATIVES 未知
公开(公告)号：CA2460177C
公开(公告)日：2010-03-23
申请号：CA2460177
申请日：2002-09-20
申请人： MITSUBISHI PHARMA CORP , SANOFI SYNTHELABO
发明人： UEHARA FUMIAKI , ARITOMO KEIICHI , SHODA AYA , HIKI SHINSUKE , OKUYAMA MASAHIRO , USUI YOSHIHIRO , OOIZUMI MITSURU , WATANABE KAZUTOSHI
IPC分类号： C07D239/36 , C07D413/14 , A61K31/506 , A61K31/513 , A61K31/5377 , A61K31/5386 , A61P3/04 , A61P3/10 , A61P17/14 , A61P25/02 , A61P25/16 , A61P25/18 , A61P25/28 , A61P27/02 , A61P27/06 , A61P35/00 , A61P35/02 , A61P43/00 , C07D239/34 , C07D239/40 , C07D239/46 , C07D239/47 , C07D239/56 , C07D401/04 , C07D401/14 , C07D413/04 , C07D417/14 , C07D498/10
摘要： A pyrimidone derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof having inhibitory activity against tau protein kinase 1:wherein R1 represents a C1-C12 alkyl group which may be substituted;R represents, for example, a group represented by the following formula (II):wherein R2 and R3 independently represent a hydrogen atom or a C1-C8 alkyl group; R4 represents a benzene ring which may be substituted, a naphthalene ring which may be substituted, an indan ring which may be substituted, a tetrahydronaphthalene ring which may be substituted, or an optionally substituted heterocyclic ring having 1 to 4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom, and having 5 to 10 ring-constituting atoms in total.

5. 发明专利

PL368671A1 3-SUBSTITUTED-4-PYRIMIDONE DERIVATIVES 未知
公开(公告)号：PL368671A1
公开(公告)日：2005-04-04
申请号：PL36867102
申请日：2002-09-20
申请人： MITSUBISHI PHARMA CORP , SANOFI SYNTHELABO
发明人： UEHARA FUMIAKI , ARITOMO KEIICHI , SHODA AYA , HIKI SHINSUKE , OKUYAMA MASAHIRO , USUI YOSHIHIRO , OOIZUMI MITSURU , WATANABE KAZUTOSHI , YAMAKOSHI KOICHI
IPC分类号： C07D239/40 , A61K31/513 , A61K31/5377 , A61K31/5386 , A61P3/04 , A61P3/10 , A61P9/10 , A61P17/14 , A61P25/00 , A61P25/16 , A61P25/18 , A61P25/24 , A61P25/28 , A61P27/02 , A61P27/06 , A61P35/00 , A61P35/02 , A61P43/00 , C07D239/34 , C07D239/46 , C07D239/56 , C07D401/04 , C07D401/14 , C07D413/14 , C07D417/14 , C07D498/10 , A61K31/505
摘要： A pyrimidone derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof having inhibitory activity against tau protein kinase 1: wherein R 1 represents a C 1 -C 12 alkyl group which may be substituted; R represents, for example, a group represented by the following formula (II): wherein R 2 and R 3 independently represent a hydrogen atom or a C 1 -C 8 alkyl group; R 4 represents a benzene ring which may be substituted, a naphthalene ring which may be substituted, an indan ring which may be substituted, a tetrahydronaphthalene ring which may be substituted, or an optionally substituted heterocyclic ring having 1 to 4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom, and having 5 to 10 ring-constituting atoms in total.

6. 发明专利

AR036604A1 DERIVADOS DE 4-PIRIMIDONA 3-SUSTITUIDA 未知
公开(公告)号：AR036604A1
公开(公告)日：2004-09-22
申请号：ARP020103547
申请日：2002-09-20
申请人： MITSUBISHI PHARMA CORP , SANOFI SYNTHELABO
发明人： UEHARA FUMIAKI , SHODA AYA , HIKI SHINSUKE , OKUYAMA MASAHIRO , OOIZUMI MITSURU , WATANABE KAZUTOSHI , USUI YOSHIHIRO , ARITOMO KEIICHI
IPC分类号： C07D239/36 , A61K31/513 , A61K31/5377 , A61K31/5386 , A61P3/04 , A61P3/10 , A61P17/14 , A61P25/02 , A61P25/16 , A61P25/18 , A61P25/28 , A61P27/02 , A61P27/06 , A61P35/00 , A61P35/02 , A61P43/00 , C07D239/34 , C07D239/40 , C07D239/46 , C07D239/56 , C07D401/04 , C07D401/14 , C07D413/04 , C07D413/14 , C07D417/14 , C07D498/10 , A61K31/505
摘要： Un derivado de pirimidona representado por la fórmula (1) o una sal del mismo, o un solvato del mismo, o un hidrato del mismo que tiene una actividad inhibidora contra la cinasa proteínica tau 1. También se reivindican un medicamento y un inhibidor de la cinasa proteínica tau 1. Dicho medicamento se usa para el tratamiento preventivo y/o terapéutico de una enfermedad causada por la hiper actividad de la cinasa proteínica tau 1, tales como: mal de Alzheimer, accidentes cerebrovasculares isquémicos, síndrome de Down, complejo de demencia y parkinsonismo de Guam, demencia vascular, danos traumáticos, traumas cerebrales y de la médula espinal, retinopatía y glaucoma. Reivindicación 1: Un derivado de pirimidona representado por la fórmula (1) o una sal del mismo, o un solvato del mismo, o un hidrato del mismo, caracterizada porque R1 representa un grupo alquilo C1-12 que puede ser sustituido; R representa cualquiera de los grupos representados por las siguientes fórmulas (2) a (5) caracterizadas porque R2 y R3 independientemente representan un átomo de hidrógeno o un grupo alquilo C1-8; R4 representa un anillo de benceno que puede ser sustituido, un anillo de naftaleno que puede ser sustituido, un anillo de indano que puede ser sustituido, un anillo de tetrahidronaftaleno que puede ser sustituido, o un anillo heterocíclico opcionalmente sustituido que tiene de 1 a 4 heteroátomos seleccionados del grupo que consiste de un átomo de oxígeno, un átomo de azufre, un átomo de nitrógeno, y tiene de 5 a 10 átomos, en total. R5 representa un grupo alquilo C1-8 que puede ser sustituido, un grupo cicloalquilo C3-8 que puede ser sustituido, un anillo de benceno que puede ser sustituido, un anillo de naftaleno que puede ser sustituido, un anillo de indano que puede ser sustituido, un anillo de tetrahidronaftaleno que puede ser sustituido, o un anillo heterocíclico opcionalmente sustituido que tiene de 1 a 4 heteroátomos seleccionados del grupo que consiste de un átomo de oxígeno, un átomo de azufre, un átomo de nitrógeno, y tiene de 5 a 10 átomos, en total. R6 representa un átomo de hidrógeno, un grupo alquilo C1-8 que puede ser sustituido, un anillo de benceno que puede ser sustituido; ó R5 y R6 pueden unirse para formar, junto con el carbono al cual se unen, un anillo espiro cíclico opcionalmente sustituido, que tiene de 3 a 11 átomos, en total, que constituyen el anillo; R7 y R8 independientemente representan un átomo de hidrógeno, o un grupo alquilo C1-8, o R7 y R8 pueden combinarse para formar un grupo alquileno C2-6; R9 y R10 representan un grupo alquilo C1-8 que puede ser sustituido, un grupo cicloalquilo C3-8 que puede ser sustituido, un anillo de benceno que puede ser sustituido, un anillo de naftaleno que puede ser sustituido, o un anillo heterocíclico opcionalmente sustituido que tiene de 1 a 4 heteroátomos seleccionados del grupo que consiste de un átomo de oxígeno, un átomo de azufre, un átomo de nitrógeno, y tiene de 5 a 10 átomos, en total, o R9 y R10 representan -N(R11)R12) caracterizados porque R11 representa un átomo de hidrógeno, un grupo alquilo C1-8; y R12 representa un grupo alquilo C1-8, un anillo de benceno que puede ser sustituido, un anillo de naftaleno que puede ser sustituido, o un anillo heterocíclico opcionalmente sustituido que tiene de 1 a 4 heteroátomos seleccionados del grupo que consiste de un átomo de oxígeno, un átomo de azufre, un átomo de nitrógeno, y que tiene de 5 a 10 átomos en total, que constituyen el anillo; y X representa CH2, O ó NR13 caracterizados porque R13 representa un átomo de hidrógeno o un grupo alquilo C1-8.

7. 发明专利

BR0212893A 未知
公开(公告)号：BR0212893A
公开(公告)日：2004-08-03
申请号：BR0212893
申请日：2002-09-20
申请人： MITSUBISHI PHARMA CORP , SANOFI SYNTHELABO
发明人： UEHARA FUMIAKI , ARITOMO KEIICHI , SHODA AYA , HIKI SHINSUKE , OKUYAMA MASAHIRO , USUI YOSHIHIRO , OOIZUMI MITSURU , WATANABE KAZUTOSHI
IPC分类号： C07D239/36 , A61K31/513 , A61K31/5377 , A61K31/5386 , A61P3/04 , A61P3/10 , A61P17/14 , A61P25/02 , A61P25/16 , A61P25/18 , A61P25/28 , A61P27/02 , A61P27/06 , A61P35/00 , A61P35/02 , A61P43/00 , C07D239/34 , C07D239/40 , C07D239/46 , C07D239/56 , C07D401/04 , C07D401/14 , C07D413/04 , C07D413/14 , C07D417/14 , C07D498/10 , A61K31/505
摘要： A pyrimidone derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof having inhibitory activity against tau protein kinase 1: wherein R1 represents a C1-C12 alkyl group which may be substituted; R represents, for example, a group represented by the following formula (II): wherein R2 and R3 independently represent a hydrogen atom or a C1-C8 alkyl group; R4 represents a benzene ring which may be substituted, a naphthalene ring which may be substituted, an indan ring which may be substituted, a tetrahydronaphthalene ring which may be substituted, or an optionally substituted heterocyclic ring having 1 to 4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom, and having 5 to 10 ring-constituting atoms in total.

8. 发明专利

CA2460121A1 3-SUBSTITUTED-4-PYRIMIDONE DERIVATIVES 未知
公开(公告)号：CA2460121A1
公开(公告)日：2003-05-08
申请号：CA2460121
申请日：2002-09-20
申请人： MITSUBISHI PHARMA CORP , SANOFI SYNTHELABO
发明人： OOIZUMI MITSURU , UEHARA FUMIAKI , WATANABE KAZUTOSHI , ARITOMO KEIICHI , YAMAKOSHI KOICHI , HIKI SHINSUKE , SHODA AYA , USUI YOSHIHIRO , OKUYAMA MASAHIRO
IPC分类号： C07D239/40 , A61K31/513 , A61K31/5377 , A61K31/5386 , A61P3/04 , A61P3/10 , A61P9/10 , A61P17/14 , A61P25/00 , A61P25/16 , A61P25/18 , A61P25/24 , A61P25/28 , A61P27/02 , A61P27/06 , A61P35/00 , A61P35/02 , A61P43/00 , C07D239/34 , C07D239/46 , C07D239/56 , C07D401/04 , C07D401/14 , C07D413/14 , C07D417/14 , C07D498/10 , A61K31/505
摘要： A pyrimidone derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof having inhibitory activity against tau protein kinase 1:wherein R1 represents a C1-C12 alkyl group which may be substituted; R represents, for example, a group represented by the following formula (II):wherein R2 and R3 independently represent a hydrogen atom or a C1- C8 alkyl group; R4 represents a benzene ring which may be substituted, a naphthalene ring which may be substituted, an indan ring which may be substituted, a tetrahydronaphthalene ring which may be substituted, or an optionally substituted heterocyclic ring having 1 to 4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom, and having 5 to 10 ring-constituting atoms in total.

9. 发明专利

CA2460121C 3-SUBSTITUTED-4-PYRIMIDONE DERIVATIVES 未知
公开(公告)号：CA2460121C
公开(公告)日：2010-11-02
申请号：CA2460121
申请日：2002-09-20
申请人： MITSUBISHI PHARMA CORP , SANOFI SYNTHELABO
发明人： UEHARA FUMIAKI , ARITOMO KEIICHI , SHODA AYA , HIKI SHINSUKE , OKUYAMA MASAHIRO , USUI YOSHIHIRO , OOIZUMI MITSURU , WATANABE KAZUTOSHI , YAMAKOSHI KOICHI
IPC分类号： C07D239/40 , C07D401/04 , A61K31/505 , A61K31/513 , A61K31/5377 , A61K31/5386 , A61P3/04 , A61P3/10 , A61P9/10 , A61P17/14 , A61P25/00 , A61P25/16 , A61P25/18 , A61P25/24 , A61P25/28 , A61P27/02 , A61P27/06 , A61P35/00 , A61P35/02 , A61P43/00 , C07D239/34 , C07D239/46 , C07D239/56 , C07D401/14 , C07D413/14 , C07D417/14 , C07D498/10
摘要： A pyrimidone derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof having inhibitory activity against tau protein kinase 1:wherein R1 represents a C1-C12 alkyl group which may be substituted; R represents, for example, a group represented by the following formula (II):wherein R2 and R3 independently represent a hydrogen atom or a C1-C8 alkyl group; R4 represents a benzene ring which may be substituted, a naphthalene ring which may be substituted, an indan ring which may be substituted, a tetrahydronaphthalene ring which may be substituted, or an optionally substituted heterocyclic ring having 1 to 4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom, and having 5 to 10 ring-constituting atoms in total.

10. 发明专利

HU0401900A2 3-SUBSTITUTED-4-PYRIMIDONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR INTERMEDIATES 未知
公开(公告)号：HU0401900A2
公开(公告)日：2004-12-28
申请号：HU0401900
申请日：2002-09-20
申请人： MITSUBISHI PHARMA CORP , SANOFI SYNTHELABO
发明人： UEHARA FUMIAKI , ARITOMO KEIICHI , SHODA AYA , HIKI SHINSUKE , OKUYAMA MASAHIRO , USUI YOSHIHIRO , OOIZUMI MITSURU , WATANABE KAZUTOSHI , YAMAKOSHI KOICHI
IPC分类号： C07D239/40 , A61K31/513 , A61K31/5377 , A61K31/5386 , A61P3/04 , A61P3/10 , A61P9/10 , A61P17/14 , A61P25/00 , A61P25/16 , A61P25/18 , A61P25/24 , A61P25/28 , A61P27/02 , A61P27/06 , A61P35/00 , A61P35/02 , A61P43/00 , C07D239/34 , C07D239/46 , C07D239/56 , C07D401/04 , C07D401/14 , C07D413/14 , C07D417/14 , C07D498/10
摘要： A pyrimidone derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof having inhibitory activity against tau protein kinase 1: wherein R 1 represents a C 1 -C 12 alkyl group which may be substituted; R represents, for example, a group represented by the following formula (II): wherein R 2 and R 3 independently represent a hydrogen atom or a C 1 -C 8 alkyl group; R 4 represents a benzene ring which may be substituted, a naphthalene ring which may be substituted, an indan ring which may be substituted, a tetrahydronaphthalene ring which may be substituted, or an optionally substituted heterocyclic ring having 1 to 4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom, and having 5 to 10 ring-constituting atoms in total.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式